PHAXIAM Therapeutics S.A. Return on Equity

PHAXIAM Therapeutics S.A. (PHXM) currently reports a ROE of -43.11%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s ROE history and peer comparisons.

PHAXIAM Therapeutics S.A.'s ROE of -43.11% is lower than the Healthcare sector average of 22.76%. That is roughly 289.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but PHAXIAM Therapeutics S.A.'s current -43.11% should be judged against Healthcare norms (sector average: 22.76%) and against PHXM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -43.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.

PHAXIAM Therapeutics S.A. is classified in the Healthcare sector. On ROE, it currently shows -43.11% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHXM with unrelated industries.